stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery
with or without hyperthermic intraperitoneal chemotherapy
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03772028.
The objective of this study is to prove that treatment with primary cytoreductive surgery
in combination with HIPEC (treatment arm) improves outcome compared to primary
cytoreductive surgery without HIPEC (standard arm) with acceptable morbidity, in patients
with FIGO stage III epithelial ovarian cancer who are eligible for primary cytoreductive
surgery with no residual disease, or residual disease up to 2.5 mm.
Lead OrganizationThe Netherlands Cancer Institute
